VolitionRx Highlights a Transformational Year: Clinical Validation, Commercial Partnerships, and Potential Upcoming Milestones
VolitionRx published a 2026 progress review citing >95% early-stage cancer detection in a blinded 81-subject Capture-Seq cohort and peer-reviewed validation of Nu.Q® NETs for predicting sepsis mortality. Revenue grew 134% year-to-date to $3.0 million, while operating costs fell 13% and convertible note debt was cut by over $5.0 million to roughly $0.7 million.
Key figures
- Revenue
- 3000000
- Revenue Yoy
- 134%
- Patents
- over 70
- Licensing discussions
- more than a dozen diagnostic companies
- Detecseps program value
- €6.3 million (~$7.3 million)
- Feline lymphoma detection
- 86% at 97% specificity
- Ytd operating cost change
- -13%
- Ytd operating loss change
- -24%
- Potential feline milestone
- $5 million
- Capture seq sensitivity stage1
- 94%
- Capture seq sensitivity stage2
- 96%
- Capture seq overall sensitivity
- 93% at 95% specificity
- Convertible note debt reduction
- $5.0 million
- Remaining convertible note principal
- ~$0.7 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.